Phosphodiesterase 5 inhibitors in vascular systemic disorders

被引：4
作者：
Allanore, Yannick [1 ]
机构：
[1] Univ Paris 05, INSERM U1016, Serv Rhumatol, Hop Cochin, F-75014 Paris, France
来源：
JOINT BONE SPINE | 2012年 / 79卷 / 04期
关键词：
Phosphodiesterase; Nitric oxide; Pulmonary hypertension; Raynaud's phenomenon; Sildenafil; Tadalafil; PULMONARY ARTERIAL-HYPERTENSION; RAYNAUDS-PHENOMENON RESISTANT; DOUBLE-BLIND; SILDENAFIL; THERAPY; TADALAFIL; SCLEROSIS; EFFICACY;
D O I：
10.1016/j.jbspin.2011.12.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：338 / 340
页数：3
相关论文
共 50 条
[21]   Phosphodiesterase 5 inhibitors and erectile dysfunction [J].
Sandner, Peter ;
Svenstrup, Niels ;
Tinel, Hanna ;
Haning, Helmut ;
Bischoff, Erwin .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2008, 18 (01) :21-33
[22]   Cardiovascular effects of phosphodiesterase 5 inhibitors [J].
Reffelmann, Thorsten ;
Kloner, Robert A. .
CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (27) :3485-3494
[23]   Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review [J].
Shafiee, Arman ;
Bahri, Razman Arabzadeh ;
Teymouri Athar, Mohammad Mobin ;
Afsharrezaei, Fatemeh ;
Gholami, Mostafa .
BMC GASTROENTEROLOGY, 2023, 23 (01)
[24]   Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis [J].
Abbasi, Behzad ;
Shaw, Nathan M. ;
Lui, Jason L. ;
Hakam, Nizar ;
Nabavizadeh, Behnam ;
Breyer, Benjamin N. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (01)
[25]   Phosphodiesterase-5 inhibitors and rosacea: report of 10 cases [J].
Ioannides, D. ;
Lazaridou, E. ;
Apalla, Z. ;
Devliotou-Panagiotidou, D. .
BRITISH JOURNAL OF DERMATOLOGY, 2009, 160 (03) :719-720
[26]   Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension [J].
Kilickesmez, Kadriye ;
Kucukoglu, M. Serdar .
ANATOLIAN JOURNAL OF CARDIOLOGY, 2010, 10 :16-18
[27]   Effects of phosphodiesterase type 5 inhibitors on Raynaud’s phenomenon [J].
Yasuyuki Kamata ;
Seiji Minota .
Rheumatology International, 2014, 34 :1623-1626
[28]   Therapeutic Potentials of Phosphodiesterase-5 Inhibitors in Cardiovascular Disease [J].
Ha Nguyen ;
Amanullah, Aman M. .
REVIEWS IN CARDIOVASCULAR MEDICINE, 2014, 15 (02) :158-167
[29]   Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey [J].
N N Kim .
International Journal of Impotence Research, 2003, 15 :S13-S19
[30]   Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey [J].
Kim, NN .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2003, 15 (Suppl 5) :S13-S19
12345